DK2173376T3 - Multimere multiepitop-influenzavacciner - Google Patents

Multimere multiepitop-influenzavacciner Download PDF

Info

Publication number
DK2173376T3
DK2173376T3 DK08789738.5T DK08789738T DK2173376T3 DK 2173376 T3 DK2173376 T3 DK 2173376T3 DK 08789738 T DK08789738 T DK 08789738T DK 2173376 T3 DK2173376 T3 DK 2173376T3
Authority
DK
Denmark
Prior art keywords
leu
gly
thr
arg
glu
Prior art date
Application number
DK08789738.5T
Other languages
English (en)
Inventor
Tamar Ben-Yedidia
Yossi Singer
Original Assignee
Biondvax Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondvax Pharmaceuticals Ltd filed Critical Biondvax Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK2173376T3 publication Critical patent/DK2173376T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (10)

1. Multimert multiepitop-polypeptid, som omfatter flere kopier af en flerhed af influen-zaviruspeptidepitoper, der er arrangeret i en konfiguration valgt blandt en skiftende sekventiel polymer struktur (X1X2X3..X9)n og en blokcopolymerstruktur
hvor n ved hver forekomst uafhængigt er et helt tal på 3-5; og hver af X1-X9 er en forskellig influenzapeptidepitop, som er valgt fra gruppen bestående af HA 354-372 svarende til E1 og SEQ ID NO: 82, HA 91-108 svarende til E2 og SEQ ID NO: 48, M1 2-12 svarende til E3 og SEQ ID NO: 25, HA 150-159 svarende til E4 og SEQ ID NO: 52, HA 143-149 svarende til E5 og SEQ ID NO: 51, NP 206-229 svarende til E6 og SEQ ID NO: 64, HA 307-319 svarende til E7 og SEQ ID NO: 59, NP 335-350 svarende til E8 og SEQ ID NO: 69, og NP 380-393 svarende til E9 og SEQ ID NO: 70.
2. Polypeptid ifølge krav 1, som omfatter: (i) ni forskellige influenzaviruspeptidepitoper, som er arrangeret i følgende skiftende polymere struktur [E1 E2E3E4E5E6E7E8E9]n, hvor n er 3 eller 5; eller (ii) tre repeats af ni forskellige influenzaviruspeptidepitoper, som er arrangeret i følgende blokcopolymerstruktur [E1E1E1-E2E2E2-E3E3E3-E4E4E4-E5E5E5-E6E6E6-E7E7E7-E8E8E8-E9E9E9].
3. Polypeptid ifølge krav 1 som vist i en sekvens, der er valgt fra gruppen bestående af SEQ ID NO:84, SEQ ID NO:86 og SEQ ID NO:88.
4. Polypeptid ifølge krav 1, som desuden omfatter en bærersekvens.
5. Isoleret polynukleotid, som koder for et influenza-multiepitop-polypeptid ifølge et hvilket som helst af kravene 1-3.
6. Isoleret polynukleotid ifølge krav 5, som koder for en polypeptidsekvens, der er valgt fra gruppen bestående af SEQ ID NO:84, SEQ ID NO:86 og SEQ ID NO:88; eller omfatter en sekvens, der er valgt fra gruppen bestående af: SEQ ID NO:83, SEQ ID NO:85 og SEQ ID NO:87.
7. Vaccine til immunisering af et individ mod influenza, omfattende mindst ét polypeptid ifølge krav 1.
8. Vaccine ifølge krav 7, som desuden omfatter en adjuvans.
9. Vaccine ifølge et hvilket som helst af kravene 7 eller 8 til anvendelse til induktion af et immunrespons og tilvejebringelse af beskyttelse mod influenza.
10. Anvendelse af et polypeptid ifølge et hvilket som helst af kravene 1-4 til fremstilling af et vaccinepræparat til immunisering mod influenza.
DK08789738.5T 2007-08-02 2008-08-03 Multimere multiepitop-influenzavacciner DK2173376T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95349807P 2007-08-02 2007-08-02
PCT/IL2008/001062 WO2009016639A2 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines

Publications (1)

Publication Number Publication Date
DK2173376T3 true DK2173376T3 (da) 2015-06-29

Family

ID=40305020

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08789738.5T DK2173376T3 (da) 2007-08-02 2008-08-03 Multimere multiepitop-influenzavacciner

Country Status (18)

Country Link
US (2) US8747861B2 (da)
EP (1) EP2173376B1 (da)
JP (1) JP5654345B2 (da)
KR (1) KR101580660B1 (da)
CN (1) CN101795709B (da)
AU (1) AU2008281384C1 (da)
BR (1) BRPI0815008B8 (da)
CA (1) CA2695399C (da)
DK (1) DK2173376T3 (da)
EA (1) EA017887B1 (da)
ES (1) ES2539818T3 (da)
HK (1) HK1142809A1 (da)
HR (1) HRP20150479T1 (da)
HU (1) HUE025149T2 (da)
MX (1) MX2010001284A (da)
PL (1) PL2173376T3 (da)
PT (1) PT2173376E (da)
WO (1) WO2009016639A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) * 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
WO2009128951A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of respiratory synctial virus proteins and methods of use
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
CN105727250B (zh) 2010-08-23 2023-11-07 康干细胞生物科技有限公司 预防和治疗免疫病变和炎性疾病的药物组合物
WO2012115715A2 (en) * 2011-02-21 2012-08-30 Vaxinnate Corporation Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US9580475B2 (en) * 2011-06-20 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
WO2013037804A1 (en) * 2011-09-12 2013-03-21 Laboratorios Del Dr. Esteve, S.A. Method for monitoring cytotoxic t lymphocyte (ctl) responses by a delayed-type hypersensitivity reaction using defined ctl viral epitopes
CA3207612A1 (en) * 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US20150056231A1 (en) * 2012-04-02 2015-02-26 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
CN103055311B (zh) * 2012-12-28 2014-05-21 中山大学 一种传染性喉气管炎粘膜疫苗及其制备方法和应用
WO2014108515A1 (en) * 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
US10426828B2 (en) * 2014-04-03 2019-10-01 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
RU2022108149A (ru) * 2016-02-03 2022-05-05 СиДжи ДИСКАВЕРИ, ИНК. Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
MX2019007924A (es) 2016-12-28 2020-01-27 Invvax Inc Vacunas contra la influenza.
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
WO2019124557A1 (ja) * 2017-12-21 2019-06-27 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
WO2020051766A1 (zh) * 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
EP3986447A4 (en) * 2019-06-18 2023-08-16 Citranvi Biosciences, LLC RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES
BR112022016220A2 (pt) * 2020-02-14 2022-10-25 Univ Washington Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção
WO2022061297A1 (en) * 2020-09-21 2022-03-24 Brown Kathlynn C Targeted antigen delivery system and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9201139D0 (en) 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
WO1994006421A1 (en) 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine
US5683695A (en) 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
PT812593E (pt) 1993-03-23 2002-01-30 Smithkline Beecham Biolog Vacinas contendo monofosforil-lipido a 3-o-desacilado na sua composicao
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DK0996451T3 (da) 1997-05-20 2005-05-23 Galenica Pharmaceuticals Inc Triterpensaponinanaloger med adjuvans- og immunstimulatorisk aktivitet
JP5132851B2 (ja) 1997-08-05 2013-01-30 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2201551T3 (es) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
CA2314934C (en) 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
GB9807805D0 (en) 1998-04-09 1998-06-10 Smithkline Beecham Biolog Vaccine
JP2002511423A (ja) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
KR100682154B1 (ko) 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
JP2002523430A (ja) 1998-08-21 2002-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 熱帯熱マラリア原虫に対する組換え多価マラリアワクチン
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU6226100A (en) 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1225907A4 (en) 1999-10-05 2005-06-22 Epimmune Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
US6843781B2 (en) 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
DE60130987T2 (de) 2000-06-23 2008-07-24 Wyeth Holdings Corp. Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
WO2004003145A2 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2006519775A (ja) 2003-03-07 2006-08-31 メルク　エンド　カムパニー　インコーポレーテッド インフルエンザウイルスワクチン
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
JP5094407B2 (ja) * 2004-12-16 2012-12-12 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用
NZ556004A (en) 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
US7260958B2 (en) 2005-09-14 2007-08-28 National Taipei University Technology Electrohydrodynamic condenser device
EP1945253A2 (en) 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
PT1968632E (pt) * 2005-12-06 2012-07-16 Yeda Res & Dev Vacina da gripe melhorada
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
CA2658559A1 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
US20090196915A1 (en) 2007-08-21 2009-08-06 Gary Van Nest Composition and methods of making and using influenza proteins

Also Published As

Publication number Publication date
US20140286982A1 (en) 2014-09-25
EA201070219A1 (ru) 2010-08-30
ES2539818T3 (es) 2015-07-06
US9353159B2 (en) 2016-05-31
EP2173376A2 (en) 2010-04-14
WO2009016639A3 (en) 2009-04-30
WO2009016639A2 (en) 2009-02-05
CA2695399A1 (en) 2009-02-05
HUE025149T2 (hu) 2016-01-28
EP2173376B1 (en) 2015-03-25
CN101795709A (zh) 2010-08-04
PL2173376T3 (pl) 2015-08-31
JP5654345B2 (ja) 2015-01-14
EA017887B1 (ru) 2013-03-29
AU2008281384A1 (en) 2009-02-05
MX2010001284A (es) 2010-08-31
KR101580660B1 (ko) 2015-12-28
BRPI0815008B1 (pt) 2019-11-19
US20110182974A1 (en) 2011-07-28
CA2695399C (en) 2017-10-17
HK1142809A1 (en) 2010-12-17
BRPI0815008B8 (pt) 2021-05-25
PT2173376E (pt) 2015-07-30
KR20100045473A (ko) 2010-05-03
CN101795709B (zh) 2013-07-17
HRP20150479T1 (hr) 2015-07-17
JP2010535026A (ja) 2010-11-18
AU2008281384B2 (en) 2012-02-16
US8747861B2 (en) 2014-06-10
AU2008281384C1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
DK2173376T3 (da) Multimere multiepitop-influenzavacciner
EP1968632B1 (en) Improved influenza vaccine
US20230090311A1 (en) Self-assembling, self-adjuvanting system for delivery of vaccines
CA2828068C (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP5901084B2 (ja) ペプチドアジュバント
EP4146258A1 (en) Click omvs
IL191977A (en) Influenza vaccine